MOTS-c, muscle and movement.
A naturally occurring peptide connects energy signaling with muscle. Treatment claims need their own human evidence.
Muscle and movement
MOTS-c is a peptide made from 16 amino acids and encoded in mitochondrial genetic material. Mitochondria help cells turn nutrients into usable energy. MOTS-c has been measured in human blood and muscle, making it part of the study of how the body responds to activity and metabolic stress.
The 2021 performance paper reported that exercise increased naturally occurring MOTS-c in muscle and circulation. In the same line of work, administering MOTS-c improved running, grip and gait measures in mice, including aged mice.
The treatment performance results came from mice. They do not establish improved stair climbing, endurance or strength after MOTS-c treatment in people. A response to exercise and the effects of adding a peptide are separate questions.
How cells respond to energy stress
The 2015 founding study linked MOTS-c to glucose handling and insulin sensitivity in cell and mouse experiments. In mice, it helped prevent insulin resistance and obesity in a high-fat-diet setting. Those are findings from a particular experimental model, rather than established treatment effects in people.
The work implicated AMPK, a protein that helps cells respond to their energy conditions. Changes in folate and purine-making pathways were part of that response. Purines are building blocks cells use for genetic material and other essential processes.
A 2018 cell study found that metabolic stress moved MOTS-c into the nucleus, where it helped regulate stress-response genes. These observations describe cellular signaling. They cannot establish how much an administered peptide would reach a person’s tissues, or what the overall effect would be.
Different tissues, different findings
The 2024 CK2 study identified casein kinase 2, known as CK2, as a direct molecular target. MOTS-c bound and activated this enzyme in cell-free experiments. In mouse work, CK2 activity increased in muscle and decreased in fat.
Researchers connected those tissue-specific responses with muscle glucose uptake and prevention of atrophy, the loss of muscle tissue. The result adds detail to the mechanism. It also shows why a general claim about increasing energy can hide important differences between tissues.
The 2023 review of MOTS-c biology places the muscle and stress-response work in a broader context. A coherent mechanism can make a treatment worth investigating. It still needs human intervention studies to establish meaningful benefits and an acceptable safety profile.
Natural levels and added MOTS-c
Measuring the body’s own MOTS-c does not answer what administering extra MOTS-c will do. Natural production, circulating levels and a prepared compound involve different questions about exposure, distribution and response.
The distinction also applies to the phrase “exercise mimetic.” A compound can affect a pathway that responds to exercise without reproducing all the effects of physical activity. The mouse performance findings do not establish a replacement for exercise in people.
Human treatment efficacy remains unresolved in the research discussed here. These studies also do not establish a sleep benefit, a useful treatment hour or a human dosing schedule. The NAD+ page covers a different evidence base: trials in which people received oral precursors, rather than MOTS-c.
Human safety and regulatory limits
MOTS-c has no FDA-approved human indication. The available research does not establish a safe human treatment dose or long-term safety. FDA has identified gaps in basic safety testing and concerns about immune reactions to prepared peptide products. The body making a peptide does not establish that administering it is safe.
On the FDA safety page current as of April 22, 2026, MOTS-c appears among substances nominated but withdrawn. The accompanying safety concerns remain. A withdrawn nomination gives MOTS-c no FDA clearance, no Category 1 status and no approval for compounding.
Uncertain identity, purity and sterility add further concerns for research-use material. A laboratory label does not answer those treatment questions. The next step in understanding the science is to distinguish a promising experimental effect from the evidence needed for personal medical care. The source list keeps those experiments accessible without turning them into recommendations.